Alivexis and Astellas Pharma Announce Collaborative Research on New Drug Discovery Targets

AI Summary (NQ-processed)

Alivexis, Inc. (Headquarters: Minato-ku, Tokyo, CEO: Shun Kimura) announced on March 26, 2026, the signing of a second collaborative research agreement with Astellas Pharma Inc. This follows a previous joint research project started in June 2024. The new project aims to discover new small molecule compounds for drug targets selected by Astellas, utilizing Alivexis's computational drug discovery platform, including ModBind™, to create innovative therapeutic drugs.